Evidence map›Paper›PMID 28786798›Full record

ArticleThe international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease2017

Prevalence of pyrazinamide resistance and Wayne assay performance analysis in a tuberculosis cohort in Lima, Peru.

R I Calderón, G E Velásquez, M C Becerra, Z Zhang, C C Contreras, R M Yataco, J T Galea, L W Lecca, A L Kritski, M B Murray and 1 more

Open access · greenAbstract readComparative Study
In one paragraph

Article in The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. QuantitativeJournal of clinical microbiology · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Eliminating tuberculosis in Latin America: making it the point.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

R I CalderónSocios En Salud Sucursal Peru, Lima, Peru; Faculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
G E VelásquezDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
M C BecerraDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Z ZhangDivision of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
C C ContrerasSocios En Salud Sucursal Peru, Lima, Peru.
R M YatacoSocios En Salud Sucursal Peru, Lima, Peru.
J T GaleaSocios En Salud Sucursal Peru, Lima, Peru.
L W LeccaSocios En Salud Sucursal Peru, Lima, Peru.
A L KritskiFaculdade de Medicina, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
M B MurrayDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA; Department of Epidemiology, Harvard T H Chan School of Public Health, Boston, Massachusetts, USA.
C D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA; Division of Global Health Equity, Brigham and Women's Hospital, Boston, Massachusetts, USA.
EsSALUD · PEHarvard University · USBrigham and Women's Hospital · USUniversidade Federal do Rio de Janeiro · BR

Funding

Sequencing CoreU19AI109755 · NIAID · HARVARD MEDICAL SCHOOL · PI MURRAY, MEGAN B · 2014 to 2018
$29.1M
Real-time surveillance to support dynamic and predictive models of MDR/XDR TBU19AI076217 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI BECERRA, MERCEDES C · 2007 to 2011
$13.5M
PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Epidemiology of multidrug-resistant tuberculosis in PeruU01AI057786 · NIAID · HARVARD MEDICAL SCHOOL · PI BECERRA, MERCEDES C · 2009 to 2010
$1.2M
NIAID NIH HHS L30 AI120170NIAID NIH HHS T32 AI007433NIAID NIH HHS U01 AI057786NIAID NIH HHS U19 AI076217NIAID NIH HHS U19 AI109755
6 · The paper itself

Abstract

backgroundMultidrug-resistant tuberculosis (MDR-TB) regimens often contain pyrazinamide (PZA) even if susceptibility to the drug has not been confirmed. This gap is due to the limited availability and reliability of PZA susceptibility testing.

objectivesTo estimate the prevalence of PZA resistance using the Wayne assay among TB patients in Lima, Peru, to describe characteristics associated with PZA resistance and to compare the performance of Wayne with that of BACTEC™ MGIT™ 960.

methodsPZA susceptibility using the Wayne assay was tested in patients diagnosed with culture-positive pulmonary TB from September 2009 to August 2012. Factors associated with PZA resistance were evaluated. We compared the performance of the Wayne assay to that of MGIT 960 in a convenience sample.

resultsThe prevalence of PZA resistance was 6.6% (95%CI 5.8-7.5) among 3277 patients, and 47.7% (95%CI 42.7-52.6) among a subset of 405 MDR-TB patients. In multivariable analysis, MDR-TB (OR 86.0, 95%CI 54.0-136.9) and Latin American-Mediterranean lineage (OR 3.40, 95%CI 2.33-4.96) were associated with PZA resistance. The Wayne assay was in agreement with MGIT 960 in 83.9% of samples (κ 0.66, 95%CI 0.56-0.76).

conclusionPZA resistance was detected using the Wayne assay in nearly half of MDR-TB patients in Lima. This test can inform the selection and composition of regimens, especially those dependent on additional resistance.

Indexed as

AdolescentAdultAgedAntitubercular AgentsCohort StudiesDrug Resistance, BacterialFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMultivariate AnalysisPeruPrevalenceProspective StudiesPyrazinamideAntitubercular AgentsPyrazinamide

Identifiers

PMID28786798
PMCPMC5555119
OpenAlexW2742333015

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.